Physician profile
Rona Marc
NPI 1801167945
$5,196.94
in general payments reported to CMS, 2019-2025
25 companies · $1,180 in 2025
The $1,180 reported for 2025 was more than what 83% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $807 · 2022: $773 · 2023: $1,154 · 2024: $1,283 · 2025: $1,180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,385 · Education: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,384.84 |
| Education | $232.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $913.07 | 2021-2025 | Tremfya |
| Abbvie INC. | $727.80 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $550.36 | 2023-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $484.04 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $444.87 | 2021-2025 | |
| Incyte Corporation | $442.81 | 2021-2025 | Opzelura |
| Ucb, INC. | $330.49 | 2021-2025 | Bimzelx |
| Dermavant Sciences, INC. | $235.55 | 2023-2024 | Vtama |
| Leo Pharma INC. | $174.77 | 2022-2025 | Adbry, Anzupgo |
| Revance Therapeutics, INC. | $145.27 | 2025 | Daxxify |
| Pfizer INC. | $141.24 | 2021-2025 | |
| Merz North America, INC. | $107.81 | 2023-2024 | Xeomin |
| Arcutis Biotherapeutics, INC. | $74.80 | 2024-2025 | Zoryve |
| Lilly USA, LLC | $74.28 | 2022-2024 | Olumiant, Taltz |
| Sun Pharmaceutical Industries INC. | $50.39 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $46.88 | 2023 | Otezla |
| Genzyme Corporation | $46.74 | 2024-2025 | |
| Organon LLC | $45.14 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $38.22 | 2024 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $29.70 | 2021-2022 | |
| Almirall LLC | $26.58 | 2021 | |
| Allergan, INC. | $17.60 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $17.54 | 2025 | Dupixent |
| Dermira, INC. | $16.91 | 2021 | |
| Mission Pharmacal Company | $14.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rona Marc listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.